Logo for CytomX Therapeutics Inc

CytomX Therapeutics Investor Relations Material

Latest events

Logo for CytomX Therapeutics Inc

Q3 2024

CytomX Therapeutics
Logo for CytomX Therapeutics

Q3 2024

7 Nov, 2024
Logo for CytomX Therapeutics

Q2 2024

8 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from CytomX Therapeutics Inc

Access all reports
CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. The company utilizes its proprietary Probody® platform to create antibody-based therapies that target cancer cells while minimizing damage to healthy tissues. CytomX’s approach aims to improve the safety and effectiveness of existing cancer therapies by activating its drugs only in the tumor microenvironment. The company's development pipeline includes therapeutic candidates designed for a variety of cancers, with the goal of addressing unmet medical needs in oncology. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.